[{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Purified Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SER-301","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Firmicute species bacterial spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Encapsulated purified suspension","sponsorNew":"Seres Therapeutics \/ Nestle","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestle"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Firmicute species bacterial spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestl\u00e9 Health Science"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Bacthera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Firmicute Species Bacterial Spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Seres Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Seres Therapeutics"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SER-109","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SER-109","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Oaktree Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Oaktree Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Seres Therapeutics \/ Oaktree Capital Management"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores Live","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestl\u00e9 Health Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Seres Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"14","companyTruncated":"Seres Therapeutics \/ Nestl\u00e9 Health Science"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Seres Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Seres Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.

                          Brand Name : SER-155

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 12, 2024

                          Lead Product(s) : SER-155,Vancomycin Hydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Seres Therapeutics has signed an agreement with Nestlé Health Science to sell its VOWST, an FDA-approved oral therapy for preventing recurrent Clostridioides difficile infections (CDI).

                          Brand Name : Vowst

                          Molecule Type : Large molecule

                          Upfront Cash : $250.0 million

                          August 06, 2024

                          Lead Product(s) : Fecal Microbiota Spores, Live

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Nestlé Health Science

                          Deal Size : $525.0 million

                          Deal Type : Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Nestlé will acquire certain assets associated with VOWST (fecal microbiota spores), the first and only FDA approved oral therapeutic to prevent recurrence of Clostridioides difficile infection.

                          Brand Name : Vowst

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 06, 2024

                          Lead Product(s) : Fecal Microbiota Spores Live

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Nestle Health Sciences SA

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).

                          Brand Name : Vowst

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 05, 2023

                          Lead Product(s) : Fecal Microbiota Spores Live-brpk

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Nestle Health Sciences SA

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The agreement aimed to jointly commercialize Vowst (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibiotic treatment for recurrent CDI, follo...

                          Brand Name : Vowst

                          Molecule Type : Large molecule

                          Upfront Cash : $175 million

                          May 30, 2023

                          Lead Product(s) : Fecal Microbiota Spores Live-brpk

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Nestle Health Sciences SA

                          Deal Size : $525 million

                          Deal Type : Agreement

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The financing will support the commercial launch of Vowst, the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibacterial treatment for recurrent CDI and to fund company's pipe...

                          Brand Name : Vowst

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 27, 2023

                          Lead Product(s) : Fecal Microbiota Spores Live-brpk

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Oaktree Capital Management

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).

                          Brand Name : Vowst

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 26, 2023

                          Lead Product(s) : Fecal Microbiota Spores Live-brpk

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Nestle Health Sciences SA

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SER-109 is an oral microbiome therapeutic candidate consisting consortium of highly purified Firmicutes spores. It is designed to prevent further recurrences of CDI by modulating the disrupted microbiome to a state that resists C. difficile colonization ...

                          Brand Name : SER-109

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 14, 2023

                          Lead Product(s) : Firmicute Species Bacterial Spores

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SER-155 composition aims to decrease the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infe...

                          Brand Name : SER-155

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 08, 2023

                          Lead Product(s) : SER-155,Vancomycin Hydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SER-109 (Firmicute Species Bacterial Spores) is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome.

                          Brand Name : SER-109

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 26, 2022

                          Lead Product(s) : Firmicute Species Bacterial Spores

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank